Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | EVP, General Counsel | June 25, 2026 | June 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date June 25, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-06-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-25 · Exercise / conversion · Acquired 1,000 · Balance 1,000 F1: The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms. Row 2 · 2026-06-25 · Sale · Disposed 1,000 · Balance 0 F1: The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $179.25 · Expires 2035-02-27 | Direct | 6,500 |
Reported balance
After 2026-06-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-25 · Exercise / conversion · Disposed 1,000 · Balance 6,500 F2: The options vest ratably over a four-year period beginning on February 28, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms.
F2: The options vest ratably over a four-year period beginning on February 28, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 26, 2026 22:45 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $179.25 | $0.00 |
DisclosureSEC source: 0002114900-26-000009 · wk-form4_1782513949.xml · derivative · entry 3 Thomas John Charles · CIK 0002114900 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 1,000 shares Expires 2035-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest ratably over a four-year period beginning on February 28, 2026. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 22:45 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,000 | $347.27 | $347,270.00 |
DisclosureSEC source: 0002114900-26-000009 · wk-form4_1782513949.xml · nonDerivative · entry 2 Thomas John Charles · CIK 0002114900 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · shares: The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 22:45 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 1,000 | $179.25 | $179,250.00 |
DisclosureSEC source: 0002114900-26-000009 · wk-form4_1782513949.xml · nonDerivative · entry 1 Thomas John Charles · CIK 0002114900 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms. Read SEC document |
| May 26, 2026 Filed May 27, 2026 21:17 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 642 | $302.03 | $193,903.26 |
DisclosureSEC source: 0002114900-26-000006 · wk-form4_1779916673.xml · nonDerivative · entry 1 Thomas John Charles · CIK 0002114900 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. The Rule 10b5-1 trading plan will terminate on December 31, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.